– created to break the skin barrier in a minimally invasive way similar to the nicotine patch. Their innovative design means they can be engineered to identify and track specific biomarkers in the skin.
In this new big project, Dr. Sharma will lead a consortium of leading scientists from Swansea University, Imperial College London and the University of Glasgow. Dr. Kaori Tsukakoshi will lead the researchers from Japan together with the Tokyo University of Agriculture and Technology and the National Institute of Quantum Science and Technology.
Swansea University Dr. Sanjiv Sharma comments:
“Alzheimer’s disease (AD) is the most common form of dementia. It is currently untreated and associated with a high social and family burden, national health systems are not prepared for it and is a major challenge for sustainable development.
Advertising
More than one million people in the UK are predicted to suffer from dementia by 2025, with a huge financial and social impact on the UK economy of £26 billion in the current year. Similarly, Japan’s aging population is witnessing an increase in AD. The increase in the prevalence of AH cases in those aged 60 years and older from 3.5 million cases in 2016 to 4.9 million cases in 2026 corresponds to an annual growth rate of 4%. Similar trends are observed on a global scale.
As disease-modifying treatment (DMT) for AD becomes a possibility, evidence highlights the importance of early diagnosis based on readily available biomarkers, suggesting that any effective prevention or DMT must start very early in the disease process.
Dr. from Tokyo University of Agriculture and Technology. Kaori Tsukakoshi comments:
“Over the past decade, blood biomarkers for AD diagnosis have been extensively researched and are finally being developed. Our collaborative research focused on the development of a Point-of-Care Test device for AD biomarkers will facilitate a new diagnostic process for AD. This will allow more AD patients to be referred to the upcoming DMT for AD.” will give.”
This is a multidisciplinary research project jointly funded by the Medical Research Council – UK Research and Innovation and the Japan Agency for Medical Research and Development (AMED).
Operation IMPACT is part-funded by the Welsh Government and the European Regional Development Fund through Swansea University.
Source: Eurekalert
